Essential care of critical illness must not be forgotten in the COVID-19 pandemic

20% of COVID-19 patients become critically ill with hypoxia or respiratory failure (figure).1 Critical illness, describing any acute life-threatening condition, is receiving increased attention in global health because of its large disease burden and population impact.2 Before the COVID-19 pandemic,...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet 2020-04, Vol.395 (10232), p.1253-1254
Main Authors: Baker, Tim, Schell, Carl Otto, Petersen, Dan Brun, Sawe, Hendry, Khalid, Karima, Mndolo, Samson, Rylance, Jamie, McAuley, Daniel F, Roy, Nobhojit, Marshall, John, Wallis, Lee, Molyneux, Elizabeth
Format: Article
Language:English
Subjects:
Betacoronavirus
Civil Defense
Consultancy services
Coronavirus Infections - epidemiology
Coronavirus Infections - therapy
Coronaviruses
COVID-19
Critical care
Critical Care - methods
Critical Care - standards
Critical Illness
Disease prevention
Emergency medical services
Global health
Health Planning
Hospitals
Humans
Hypoxia
Illnesses
Intensive care
Intensive care units
Medical research
Medicin och hälsovetenskap
Pandemics
Patients
Pneumonia, Viral - epidemiology
Pneumonia, Viral - therapy
Practice Guidelines as Topic
Quality of Health Care
Respiratory diseases
Respiratory distress syndrome
SARS-CoV-2
Viral diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:20% of COVID-19 patients become critically ill with hypoxia or respiratory failure (figure).1 Critical illness, describing any acute life-threatening condition, is receiving increased attention in global health because of its large disease burden and population impact.2 Before the COVID-19 pandemic, growing evidence suggested that the care of critical illness was overlooked in LRS—hospitals cannot, or do not, prioritise emergency and critical care.3 Most critically ill patients are cared for in emergency units and general wards and do not have access to advanced care in intensive care units (ICUs). [...]provision of essential care could prevent progression to multi-organ failure, reducing the burden on limited ICU capacity. DFM also reports personal fees from consultancy about acute respiratory disease for GlaxoSmithKline, Boehringer Ingelheim, and Bayer, unrelated to this Correspondence; in addition, DFM's institution has received funds from grants from the UK NIHR, Wellcome Trust, Innovate UK, and others, he has a patent issued to his institution for a treatment for acute respiratory distress syndrome, and he is Director of Research for the Intensive Care Society and NIHR Efficacy and Mechanism Evaluation Programme Director.
ISSN:0140-6736
1474-547X
1474-547X
DOI:10.1016/S0140-6736(20)30793-5